← feed

Is NCT03050151 results overdue?

Yes — results are overdue. Primary completion was 2017-11-14; the FDAAA-801 reporting deadline (2018-11-14) passed 2776 days ago and no results are posted on ClinicalTrials.gov.

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT IDNCT03050151 ↗
SponsorRegeneron Pharmaceuticals (INDUSTRY)
Public issuerREGENERON PHARMACEUTICALS, INC. — REGN (CIK 0000872589) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-11-14 (ACTUAL)
Reporting deadline2018-11-14 (completion + 365d)
Days overdue2776
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: yes
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 e6fe0e3855e1bee5… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03050151. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →